Evidence map›Paper›PMID 22498018›Full record

ReviewTrends in cardiovascular medicine2011

Humanizing thrombi in mice.

Jorge Magallon, Matthew Egalka, Thomas G Diacovo

Abstract readReview
In one paragraph

Review in Trends in cardiovascular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jorge MagallonDivision of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.
Matthew Egalka
Thomas G Diacovo
Columbia University Irving Medical Center · US

Funding

Model of Platelet Adhesion and Thrombus FormationR01HL097971 · NHLBI · CORNELL UNIVERSITY · PI DIACOVO, THOMAS G, KING, MICHAEL R. · 2010 to 2014
$2.0M
GPIb Alpha-VWF-A1 bond kinetics in health and diseaseR01HL103989 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DIACOVO, THOMAS G · 2010 to 2013
$1.6M
NHLBI NIH HHS HL097971-01NHLBI NIH HHS HL103989-01NHLBI NIH HHS R01 HL097971NHLBI NIH HHS R01 HL103989
6 · The paper itself

Abstract

Antiplatelet therapies form the cornerstone of atherothrombosis prevention, reducing the morbidity and mortality associated with cardiovascular disease. Despite these benefits, there is still an unmet need for more effective and safer pharmacological agents. To expedite this process, biological platforms that better reflect the intravascular environment in humans will be required in order to shorten drug development time, enable better determination of dosing regimes, and aid in the design of clinical studies. This article focuses on a unique genetically modified animal model that predicts the in vivo response of antiplatelet agents in humans more accurately than is currently possible using conventional murine models of thrombosis.

Indexed as

AnimalsBlood CoagulationDisease Models, AnimalFibrinolytic AgentsGenetic Predisposition to DiseaseHumansMiceMice, TransgenicPhenotypePlatelet Aggregation InhibitorsPoint MutationSpecies SpecificityThrombosisvon Willebrand FactorFibrinolytic AgentsPlatelet Aggregation Inhibitorsvon Willebrand Factor

Identifiers

PMID22498018
PMCPMC4336949
OpenAlexW2035853014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.